Taiga Nishihori

10.0k total citations
169 papers, 1.7k citations indexed

About

Taiga Nishihori is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Taiga Nishihori has authored 169 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Hematology, 68 papers in Oncology and 45 papers in Molecular Biology. Recurrent topics in Taiga Nishihori's work include Multiple Myeloma Research and Treatments (55 papers), Hematopoietic Stem Cell Transplantation (54 papers) and CAR-T cell therapy research (36 papers). Taiga Nishihori is often cited by papers focused on Multiple Myeloma Research and Treatments (55 papers), Hematopoietic Stem Cell Transplantation (54 papers) and CAR-T cell therapy research (36 papers). Taiga Nishihori collaborates with scholars based in United States, Lebanon and Belgium. Taiga Nishihori's co-authors include Mohamed A. Kharfan‐Dabaja, Melissa Alsina, Claudio Anasetti, Joseph Pidala, Mehdi Hamadani, Frederick L. Locke, Kenneth H. Shain, Ambuj Kumar, Teresa Field and Rachid Baz and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Taiga Nishihori

159 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Taiga Nishihori United States	22	984	751	390	344	244	169	1.7k
Paul Shaughnessy United States	20	1.3k 1.3×	508 0.7×	274 0.7×	494 1.4×	213 0.9×	85	1.8k
Massimo Martino Italy	23	1.1k 1.1×	750 1.0×	428 1.1×	248 0.7×	143 0.6×	152	1.8k
Sunil Abhyankar United States	21	1.2k 1.2×	482 0.6×	452 1.2×	552 1.6×	156 0.6×	140	1.9k
Leonard T. Heffner United States	21	1.1k 1.1×	717 1.0×	687 1.8×	172 0.5×	140 0.6×	68	1.7k
Carol Reynolds United States	21	971 1.0×	376 0.5×	180 0.5×	892 2.6×	136 0.6×	44	1.8k
Daniel Lysák Czechia	18	1.1k 1.1×	407 0.5×	585 1.5×	332 1.0×	260 1.1×	83	1.9k
Jeffrey Schriber United States	13	744 0.8×	333 0.4×	136 0.3×	324 0.9×	93 0.4×	22	1.1k
Paul Cannell Australia	18	519 0.5×	373 0.5×	229 0.6×	183 0.5×	225 0.9×	55	1.1k
Ho‐Jin Shin South Korea	22	944 1.0×	655 0.9×	399 1.0×	412 1.2×	192 0.8×	182	2.0k
Pietro Pioltelli Italy	23	969 1.0×	319 0.4×	195 0.5×	213 0.6×	168 0.7×	80	2.0k

Countries citing papers authored by Taiga Nishihori

Since Specialization

Citations

This map shows the geographic impact of Taiga Nishihori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taiga Nishihori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taiga Nishihori more than expected).

Fields of papers citing papers by Taiga Nishihori

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taiga Nishihori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taiga Nishihori. The network helps show where Taiga Nishihori may publish in the future.

Co-authorship network of co-authors of Taiga Nishihori

This figure shows the co-authorship network connecting the top 25 collaborators of Taiga Nishihori. A scholar is included among the top collaborators of Taiga Nishihori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taiga Nishihori. Taiga Nishihori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Freeman, Ciara L., Meghan Menges, Jeffrey Edelman, et al.. (2023). Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. Clinical Cancer Research. 29(22). 4575–4585. 8 indexed citations

Pidala, Joseph, Shernan G. Holtan, Kelly Walton, et al.. (2023). JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results. Blood. 142(Supplement 1). 2177–2177. 1 indexed citations

Freeman, Ciara L., Meghan Menges, Hien Liu, et al.. (2023). Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines. Blood. 142(Supplement 1). 1931–1931. 1 indexed citations

Taylor, Mallory, Steve W. Cole, Ruta Brazauskas, et al.. (2023). Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis. Blood Advances. 7(22). 6830–6838. 5 indexed citations

Abou‐Ismail, Mouhamed Yazan, Raphael Fraser, Leland Metheny, et al.. (2022). Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. British Journal of Haematology. 197(3). 326–338. 1 indexed citations

Bashir, Qaiser, Taiga Nishihori, Marcelo C. Pasquini, et al.. (2022). A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. Transplantation and Cellular Therapy. 29(6). 358.e1–358.e7. 5 indexed citations

Pidala, Joseph, Kelly Walton, Hany Elmariah, et al.. (2021). Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clinical Cancer Research. 27(10). 2712–2722. 15 indexed citations

Lee, Dae Hyun, Sanjay Chandrasekhar, Michael D. Jain, et al.. (2021). Abstract 9828: Active Surveillance of Cardiotoxicity with Cardiac Biomarkers During Chimeric Antigen Receptor T-Cell Therapy. Circulation. 144(Suppl_1). 2 indexed citations

Otoukesh, Salman, Hany Elmariah, Dongyun Yang, et al.. (2021). Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy. 28(2). 111.e1–111.e8. 12 indexed citations

10.

Meads, Mark B., Dario Magaletti, Joy Guingab‐Cagmat, et al.. (2021). Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma. Journal of Proteome Research. 20(6). 3134–3149. 10 indexed citations

11.

Turner, Joel G., Yan Cui, Jana L. Dawson, et al.. (2020). Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma. Cancer Research. 80(23). 5344–5354. 15 indexed citations

12.

Dean, Erin, Rahul Mhaskar, Hong Lü, et al.. (2020). High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. 4(14). 3268–3276. 146 indexed citations

13.

Perez, Ariel Perez, Christina A. Bachmeier, Aleksandr Lazaryan, et al.. (2020). Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel. Blood. 136(Supplement 1). 4–5. 3 indexed citations

14.

Brayer, Jason, Allison Distler, Mark B. Meads, et al.. (2017). HDAC11 Is a Candidate Therapeutic Target in Multiple Myeloma. Blood. 130. 1800–1800. 1 indexed citations

15.

Kharfan‐Dabaja, Mohamed A., Ambuj Kumar, Farhad Khimani, et al.. (2017). Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clinical Lymphoma Myeloma & Leukemia. 18(1). e35–e39. 16 indexed citations

16.

Ayala, Ernesto, Janelle Perkins, Jongphil Kim, et al.. (2015). Myeloablative Intravenous Pharmacokinetically Targeted Busulfan Plus Fludarabine As Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 15(6). 335–340. 6 indexed citations

17.

Salem, Karma Z., Taiga Nishihori, Mohamed A. Kharfan‐Dabaja, Pedro Horna, & Melissa Alsina. (2015). Primary plasmacytoma involving mediastinal lymph nodes. Hematology/Oncology and Stem Cell Therapy. 9(1). 26–29. 4 indexed citations

18.

Kharfan‐Dabaja, Mohamed A., Mehdi Hamadani, Tea Reljic, et al.. (2013). Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Journal of Hematology & Oncology. 6(1). 2–2. 33 indexed citations

19.

Nishihori, Taiga, Mohamed A. Kharfan‐Dabaja, José L. Ochoa-Bayona, et al.. (2011). Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. Hematology/Oncology and Stem Cell Therapy. 4(1). 1–9. 1 indexed citations

20.

Nishihori, Taiga, Mario Strazzabosco, & Muhammad Wasif Saif. (2008). Incidence and Management of Colorectal Cancer in Liver Transplant Recipients. Clinical Colorectal Cancer. 7(4). 260–266. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact